Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Launched by ABBVIE · Jun 18, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how treatment with risankizumab, a medicine approved for plaque psoriasis, affects the quality of life of adults with moderate to severe plaque psoriasis. Plaque psoriasis is a condition where the skin develops thick, red, scaly patches that can be uncomfortable and affect daily life. The study will observe about 700 adults who are already prescribed risankizumab by their doctors, following their usual treatment plan in real-life medical settings around the world.

To be eligible, participants must have a confirmed diagnosis of moderate to severe plaque psoriasis, with or without joint problems, and be starting risankizumab treatment as decided by their doctor before joining the study. People currently using other specific psoriasis treatments or with certain sleep disorders will not be eligible. Participants will continue their regular visits to their doctor or clinic as usual, with no extra tests or procedures required because of the study. They will be followed for up to 2.5 years to see how their quality of life changes with treatment. This study aims to better understand how risankizumab helps people in everyday medical care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants with a Confirmed diagnosis of moderate-to-severe plaque psoriasis with or without joint involvement according to the treating physician's clinical judgment, prior to time of enrollment.
• • Treatment with risankizumab is indicated per summary of product characteristics (SmPC) or local label and local prescribing/treatment guidelines.
• • Decision to treat with risankizumab is made prior to and independently of study participation.
• Exclusion Criteria:
• • History of a sleep disorder diagnosis which the patient is currently being treated for.
• • Current or recent (within the last 30 days) participation in an interventional clinical trial or an observational study.
• • Currently receiving other biologic treatments and/or small molecules including Janus kinase (JAK) inhibitors, tyrosine kinase 2 (TYK2) inhibitors, and phosphodiesterase 4 (PDE4) inhibitors for any reason.